Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’
Corbus Pharmaceuticals is adjusting the primary efficacy outcome of the ongoing and global RESOLVE-1 Phase 3 trial of lenabasum as a possible treatment for diffuse cutaneous systemic sclerosis (SSc). The change affects only U.S. sites involved in the study and was recommended by regulatory officials. The adjustment, a change…